{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:39:38Z","timestamp":1788230378689,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bmcl.2025.130215","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:33:29Z","timestamp":1743773609000},"page":"130215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Aptamer-modified GSH-degradable honokiol polyprodrug nanoparticles for ovarian cancer-specific targeting therapy"],"prefix":"10.1016","volume":"123","author":[{"given":"Chunhua","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmcl.2025.130215_bb0005","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/cancers12030561","article-title":"Factors in oncogenesis: viral infections in ovarian cancer","volume":"12","author":"Pathak","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130215_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmcl.2025.130215_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119986","article-title":"Nanoparticles in precision medicine for ovarian cancer: from chemotherapy to immunotherapy","volume":"591","author":"Li","year":"2020","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130215_bb0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/cells11040650","article-title":"Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements","volume":"11","author":"Akter","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130215_bb0025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/02652048.2022.2094487","article-title":"Multifunctional magnetic nanoparticles for MRI-guided co-delivery of erlotinib and L-asparaginase to ovarian cancer","volume":"39","author":"Mohaghegh","year":"2022","journal-title":"J Microencapsul"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130215_bb0030","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1039\/D1MA00969A","article-title":"Recent trends of contrast agents in ultrasound imaging: a review of the classifications and applications","volume":"3","author":"Tarighatnia","year":"2022","journal-title":"Mater Adv"},{"key":"10.1016\/j.bmcl.2025.130215_bb0035","article-title":"Engineering and quantification of bismuth nanoparticles as targeted contrast agent for computed tomography imaging in cellular and animal models","volume":"66","author":"Tarighatnia","year":"2021","journal-title":"J Drug Deliv Sci Tech"},{"key":"10.1016\/j.bmcl.2025.130215_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2022.04.007","article-title":"Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer","volume":"346","author":"Sharma","year":"2022","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130215_bb0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12645-021-00087-7","article-title":"Recent progress of graphene oxide-based multifunctional nanomaterials for cancer treatment","volume":"12","author":"Liu","year":"2021","journal-title":"Cancer Nanotechnol"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130215_bb0050","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/1061186X.2018.1428809","article-title":"Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels","volume":"26","author":"Ju","year":"2018","journal-title":"J Drug Target"},{"key":"10.1016\/j.bmcl.2025.130215_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153647","article-title":"Honokiol: a review of its pharmacological potential and therapeutic insights","volume":"90","author":"Rauf","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bmcl.2025.130215_bb0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.biopha.2018.08.054","article-title":"Honokiol: an anticancer lignan","volume":"107","author":"Rauf","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130215_bb0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejogrb.2008.02.023","article-title":"Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells","volume":"140","author":"Li","year":"2008","journal-title":"Eur J Obstet Gyn R B"},{"key":"10.1016\/j.bmcl.2025.130215_bb0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.colsurfb.2017.01.038","article-title":"Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC)","volume":"153","author":"Godugu","year":"2017","journal-title":"Colloid Surf B"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130215_bb0075","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1535-7163.MCT-11-0999","article-title":"Honokiol in combination with radiation targets notch signaling to inhibit Colon Cancer stem cells","volume":"11","author":"Ponnurangam","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130215_bb0080","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/10717544.2017.1303854","article-title":"Honokiol-loaded polymeric nanoparticles: an active targeting drug delivery system for the treatment of nasopharyngeal carcinoma","volume":"24","author":"Yang","year":"2017","journal-title":"Drug Deliv"},{"key":"10.1016\/j.bmcl.2025.130215_bb0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.carbpol.2015.06.102","article-title":"Encapsulation of honokiol into self-assembled pectin nanoparticles for drug delivery to HepG2 cells","volume":"133","author":"Zhang","year":"2015","journal-title":"Carbohydr Polym"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130215_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202302032","article-title":"Delivery strategies, structural modification, and pharmacological mechanisms of honokiol: a comprehensive review","volume":"21","author":"Pan","year":"2024","journal-title":"Chem Biodivers"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130215_bb0095","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1021\/acs.nanolett.0c01140","article-title":"Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer","volume":"20","author":"Zhou","year":"2020","journal-title":"Nano Lett"},{"key":"10.1016\/j.bmcl.2025.130215_bb0100","article-title":"Oxidation and reduction dual-responsive polymeric prodrug micelles co-delivery precisely prescribed paclitaxel and honokiol for laryngeal carcinoma combination therapy","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130215_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202109528","article-title":"Intracellular self-immolative polyprodrug with near-infrared light guided accumulation and in vivo visualization of drug release","volume":"34","author":"Cheng","year":"2022","journal-title":"Adv Mater"},{"issue":"33","key":"10.1016\/j.bmcl.2025.130215_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201700141","article-title":"ROS-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy","volume":"29","author":"Xu","year":"2017","journal-title":"Adv Mater"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130215_bb0115","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1021\/acs.nanolett.0c05028","article-title":"Dual-drug backboned Polyprodrug with a predefined drug combination for synergistic chemotherapy","volume":"21","author":"Yu","year":"2021","journal-title":"Nano Lett"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130215_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202107434","article-title":"Polyprodrug nanomedicines: an emerging paradigm for Cancer therapy","volume":"34","author":"Yang","year":"2022","journal-title":"Adv Mater"},{"issue":"15","key":"10.1016\/j.bmcl.2025.130215_bb0125","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1039\/D2CS00099G","article-title":"Degradable polyprodrugs: design and therapeutic efficiency","volume":"51","author":"Seidi","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmcl.2025.130215_bb0130","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2020.08.016","article-title":"Nano-therapeutics for modulating the tumour microenvironment: design, development, and clinical translation","volume":"327","author":"Adityan","year":"2020","journal-title":"J Control Release"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130215_bb0135","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/anie.202003563","article-title":"Nucleic acid aptamers for molecular diagnostics and therapeutics: advances and perspectives","volume":"60","author":"Li","year":"2021","journal-title":"Angew Chem Int Edit"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130215_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103550","article-title":"Aptamers and nanobodies as alternatives to antibodies for ligand-targeted drug delivery in cancer","volume":"28","author":"Sanjanwala","year":"2023","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130215_bb0145","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","article-title":"Recent progress of aptamer\u2013drug conjugates in cancer therapy","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2025.130215_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110902","article-title":"Aptamers used for biosensors and targeted therapy","volume":"132","author":"Ning","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2025.130215_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2019.115759","article-title":"Aptamer-conjugated mesoporous silica nanoparticles for simultaneous imaging and therapy of cancer","volume":"123","author":"Vandghanooni","year":"2020","journal-title":"TrAC Trend Anal Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130215_bb0160","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.7150\/thno.17826","article-title":"Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth","volume":"7","author":"Zheng","year":"2017","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130215_bb0165","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrd2241","article-title":"Development trends for monoclonal antibody cancer therapeutics","volume":"6","author":"Reichert","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130215_bb0170","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/10717544.2020.1770373","article-title":"Hyaluronic acid reduction-sensitive polymeric micelles achieving co-delivery of tumor-targeting paclitaxel\/apatinib effectively reverse cancer multidrug resistance[J]","volume":"27","author":"Zhang","year":"2020","journal-title":"Drug Deliv"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T21:02:01Z","timestamp":1745528521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25001246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":34,"alternative-id":["S0960894X25001246"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130215","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aptamer-modified GSH-degradable honokiol polyprodrug nanoparticles for ovarian cancer-specific targeting therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130215"}}